Program
Liposomal Bupivacaine
Also written as “EXPAREL”, “bupivacaine liposome injectable suspension” and “Exparel”.
Its studies are mostly in Pain, Postoperative · Pain · Bunion · Intestinal Obstruction · Hallux Valgus, led by 4 companies.
Drug pageLiposomal Bupivacaine: every studyAll 299 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pacira BioSciencesits history only | 361 open or running | phase 4since Oct 23, 2011 | Oct 23, 2011 | Jan 2027phase 1 · NCT06271265 |
| Heron Therapeutics | 10 open or running | phase 4since Sep 23, 2019 | Sep 23, 2019 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | none ahead |
| Nuance Pharma (shanghai)its history only | 10 open or running | phase 1since Nov 5, 2019 | Nov 5, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Heron Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 23, 2019First study: phase 4 study in AgnosiaFirst studyNCT04102267 · 32 enrolled · United States
TargetBeta
“Sodium channel protein type IV alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker”ChEMBL 37, by rule
Other programs on SCN4A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 63 |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 61 |
| Ranolazinerule | Gilead Sciences | phase 4 | 26 |
| Carbamazepinerule | grin-therapeutics-inc | phase 4 | 21 |
| Dronedaronerule | Sanofi | phase 4 | 18 |
| chloroprocainerule | sintetica-sa | phase 4 | 8 |
| Riluzolerule | Sanofi | phase 4 | 6 |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 2 |
| Carticainerule | Laboratoires Thea | phase 4 | 1 |
| Ropivacainerule | painreform-ltd | phase 3 | 17 |
| Quinidinerule | Otsuka | phase 3 | 17 |
| Phenytoinrule | Viatris | phase 3 | 10 |
Studies
The one study Heron Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04102267Agnosia · United States | 4 | Completed | Sep 3, 2018 | 32 |
How it is read
Names in the registry
- “EXPAREL”, 15 entries
- “bupivacaine liposome injectable suspension”, 4 entries
- “Exparel”, 3 entries
- “Exparel Injectable Product”, 2 entries
- “EXPAREL 266 mg”, 2 entries
Conditions, from the studies’ own filings
- Pain, Postoperative, 10 studies
- Pain, 7 studies
- Bunion, 3 studies
- Intestinal Obstruction, 3 studies
- Hallux Valgus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.